title: Dendritic Cell Vaccines.
abstract: Exploitation of the patient's own immune system to induce antitumor immune responses using dendritic cell (DC) immunotherapy has been established in early clinical trials as a safe and promising therapeutic approach for cancer. However, their limited success in larger clinical trials highlights the need to optimize DC vaccine preparations. This chapter describes the methodologies utilized for the preparation of the DC vaccine most commonly used in clinical trials. Optional variations at different stages in DC vaccine preparation, based on the nature of antigen, delivery of antigen, maturation stimuli, and mode of administration for DC vaccines, are also presented for consideration as these are often dependent on the disease setting, desired immune response, and/or resources available.
authors.affiliation: Division of Hematology and Medical Oncology, Department of Medicine, Icahn School of Medicine at Mount Sinai, New York, NY, 10029, USA. rachel.sabado@mssm.edu.
authors.forename: Rachel Lubong
authors.initials: RL
authors.lastname: Sabado
authors.affiliation: Division of Hematology and Medical Oncology, Department of Medicine, Icahn School of Medicine at Mount Sinai, New York, NY, 10029, USA.
authors.forename: Marcia
authors.initials: M
authors.lastname: Meseck
authors.affiliation: Division of Hematology and Medical Oncology, Department of Medicine, Icahn School of Medicine at Mount Sinai, New York, NY, 10029, USA.
authors.forename: Nina
authors.initials: N
authors.lastname: Bhardwaj
mesh_terms: D019496:Cancer Vaccines / Q000276:immunology*; D018929:Cell Culture Techniques; D002469:Cell Separation; D002986:Clinical Trials as Topic; D016207:Cytokines / Q000494:pharmacology; D003713:Dendritic Cells / Q000166:cytology* / Q000187:drug effects / Q000276:immunology*; D006801:Humans; D007167:Immunotherapy
chemical_list: D019496:Cancer Vaccines; D016207:Cytokines
keywords: Dendritic cell; Immune response; Immunotherapy; Tumor; Vaccine